Incidence of venous thromboembolism remains 'substantial' despite expert guidelines and newer risk prediction scores ...

Shares of CorMedix CRMD have witnessed a strong surge so far this year, primarily driven by the continued strong uptake of the company’s lead marketed therapy, DefenCath (Taurolidine + Heparin). The ...

CorMedix CRMD and Puma Biotechnology PBYI are small-cap biotech companies focused on the successful commercialization of ...

Novel first-in-class therapeutic targeting a key immune signaling pathway and the underlying cause of HITIt is the first and only potent, highly ...

Hepatitis B virus (HBV) infects more than 250 million people worldwide and can lead to chronic liver disease and liver cancer ...

For episodic migraine prevention, Qulipta’s dosage is either 10 milligrams (mg), 30 mg, or 60 mg once per day. For chronic migraine prevention, the typical dosage is 60 mg once per day. A dosage ...

Bristol Myers Squibb Announces Agreement with U.S. Government to Improve Affordability and Access to Critical Medicines for Americans ...

The FDA has approved Myqorzo for the treatment of adults with symptomatic oHCM to improve functional capacity and symptoms.

Antithrombin III (human) 500 IU; per vial; lyophilized pwd for IV infusion after reconstitution; preservative-free. Antithrombin, an alpha2-glycoprotein, is normally present in human plasma and is the ...

PONTE VEDRA, FL / ACCESS Newswire / December 12, 2025 / Cadrenal Therapeutics (NASDAQ:CVKD) believes it continues to be misread by the market. Yes, the Company is intentionally narrowly focused. Howev ...

PONTE VEDRA, FL / ACCESS Newswire / December 12, 2025 / Cadrenal Therapeutics (NASDAQ:CVKD) entered the back half of the year with a calm, almost surgical approach to building out its foundation. Whil ...

If you plan on getting involved in day trading, then having access to reliable and feature-rich charting platforms can be an essential tool. With numerous day trading chart providers available in the ...